#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Retatrutide: US compassionate use explained
Retatrutide is investigational. The US has opened a compassionate use pathway after Trump speculation. Here is what that means and who may qualify.
Semaglutide kidney outcomes: pooled trials
A prespecified pooled analysis of 30,787 participants finds semaglutide cuts serious kidney events by 16% (HR 0.84) vs placebo.
SGLT2 inhibitor ketoacidosis in the ICU
Two ICU cases show SGLT2 inhibitor ketoacidosis after cardiac surgery and GLP-1 co-prescription. Normal glucose levels masked the diagnosis in both patients.
Zepbound versus obesity pills
Zepbound still has strong direct trial evidence as oral obesity medicines add useful, but not automatically superior, options.
Tirzepatide vials: what the label says
Mounjaro and Zepbound use single-dose vials. Pooling drug between vials is not described in either label. Here is what the prescribing information says.
Lilly and Resilience: $750M GLP-1 capacity
Eli Lilly and contract manufacturer Resilience announced a $750M Cincinnati expansion adding 400 jobs to GLP-1 injectable production. What it means for supply.
Semaglutide cut heavy drinking in AUD trial
The SEMALCO trial found semaglutide reduced heavy drinking days by 41 percentage points versus 26 on placebo in adults with AUD and obesity.
How semaglutide is measured in plasma
A 2026 HPLC-MS/MS assay measures semaglutide in plasma at 5-200 ng/mL. Why validated bioanalytical methods matter for pharmacokinetics and product quality.
Retatrutide + GHK-Cu + ipamorelin stack
What the research says about each compound and the key data gaps before combining retatrutide, GHK-Cu, and ipamorelin with CJC-1295 No DAC.
GLP-1 and GIP: a short incretin history
Incretins went from a failed 1906 diabetes experiment to GLP-1 and GIP drugs. Here are the dates, the discoveries, and where the evidence thins out.
GLP-1 safety in neuroendocrine tumours
A 2026 European Journal of Endocrinology review weighs the evidence on GLP-1 receptor agonists like semaglutide in neuroendocrine neoplasms.
MASLD and cardiovascular risk explained
MASLD affects 38% of adults worldwide and heart disease kills more of them than liver failure. Where semaglutide fits, and what remains unproven.